

**Mouse Anti-Cytokeratin [AE1&AE3]: MC0115, MC115RTU7**

**Intended Use:** For Research Use Only

**Description:** The antibody cocktail labels simple epithelia and their tumors including cytokeratins expressed in complex stratified squamous epithelia. Positive results aid in the classification of normal and a wide range of neoplastic tissues as epithelial in origin. This antibody serves as first tier antibody for differentiation of undifferentiated neoplasm. Pan Cytokeratin clone AE1/AE3 antibody may be used with a panel of antibodies for differential diagnosis, e.g. Breast vs. lung or liver: CK7, AE1/AE3, CEA, GCDFP-15, TTF-1; Renal vs. lung or liver: AE1/AE3, CEA, TTF-1, Renal Cell Ag; Seminoma vs. lung or liver: CAM5.2, AE1/AE3, PLAP, EMA, CD30; Embryonal germ cell vs. lung or liver: AE1/AE3, TTF-1, CK7, PLAP, CD30.

**Specifications:**


Clone: AE1&AE3  
 Source: Mouse  
 Isotype: IgG1  
 Reactivity: Human  
 Localization: Cytoplasm  
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)  
 Storage: Store at 2°- 8°C  
 Applications: IHC, Flow Cyt., ICC/IF, WB  
 Package:

Description	Catalog No.	Size
Cytokeratin [AE1&AE3] Concentrated	MC0115	1ml
Cytokeratin [AE1&AE3] Prediluted	MC0115RTU7	7ml

**IHC Procedure\*:**

Positive Control Tissue: Tissue with epithelial cells (e.g. Cervix, GI track, skin, tonsil)  
 Concentrated Dilution: 100-300  
 Pretreatment: Citrate pH6.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C  
 Incubation Time and Temp: 30-60 minutes @ RT  
 Detection: Refer to the detection system manual

\* Result should be confirmed by an established diagnostic procedure.



FFPE human colon stained with anti-CK [AE1&AE3] using DAB

**References:**

1. Aberrant nonfibrotic parenchyma in idiopathic pulmonary fibrosis is correlated with decreased β-catenin inhibition and increased Wnt5a/b interaction. Rydell-Törmänen K, et al. *Physiol Rep* 4:N/A, 2016.
2. Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. Trembley JH, et al. *PLoS One* 9:e109970, 2014.
3. Combined fiber modifications both to target a(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5. Coughlan L, et al. *Hum Gene Ther* 23:960-79, 2012.